⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

A Preliminary Analysis of Oral Edaravone-treated Patients with Amyotrophic Lateral Sclerosis Enrolled in a US-based Administrative Claims Database (S3.005)

Malgorzata Ciepielewska Jeffrey Zhang Ying Liu Polina Da Silva

View at Publisher

Ask AI

Bookmark

Share

Abstract

To characterize oral edaravone-treated patients with ALS in this observational, US-based administrative claims analysis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ciepielewska et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db6435876783d4 https://doi.org/10.1212/wnl.0000000000205264

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Survival of Intravenous Edaravone–Treated Patients With <scp>ALS</scp> : Evidence From Administrative Claims AnalysesRetrospective Study · 2026 · 2 citations
2Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis2024 · 16 citations
3Adverse events in different administration routes of Edaravone: A pharmacovigilance study based on the FDA adverse event reporting systemOriginal Research · 2026 · 1 citations
4Current and Ongoing Clinical StudiesHuman Clinical Trial · 2026
5Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis2025

Safety of Intravenous Edaravone in Clinical Practice2026
Introduction to the Supplement2026
Generalizability of Edaravone Efficacy.2026
Cenobamate in Focal-Onset Refractory and Super-Refractory Status EpilepticusNeurology · 2026
Exclusion of Arteriovenous Shunts in Intracerebral Hemorrhage Using MRI Arterial Spin LabelingNeurology · 2026

More from Neurology